Fortress Biotech (NASDAQ:FBIO) PT Lowered to $15.00 at Roth Mkm

Fortress Biotech (NASDAQ:FBIO – Free Report) had its target price cut by Roth Mkm from $30.00 to $15.00 in a research note released on Wednesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently issued reports on FBIO. Cantor Fitzgerald restated an […]

Leave a Reply

Your email address will not be published.

Previous post Diamond Hill Investment Group (NASDAQ:DHIL) Downgraded to Hold at StockNews.com
Next post Cardlytics (NASDAQ:CDLX) Receives New Coverage from Analysts at Lake Street Capital